Navigation Links
Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™
Date:8/31/2011

arallel treatment groupRouteTopicalFrequencySingle application Dose Levels0.37% w/v or 0.74% w/vNumber of Subjects132Subject Selection Criteria

  • 2 years of age or older
  • Good health
  • Has an active head lice infestation as determined by an experienced evaluator

  • Primary End Points

  • Proportion of all subjects who are lice free at all follow-up visits through the Day 14 visit

  • Secondary End Points

  • Safety and tolerability of Ha44 Gel
  • Proportion of index subjects who are lice free at all follow-up visits through the Day 14 visit
  • Proportion of all subjects who are lice free at each follow-up study visit (Day 1, 7, 14)
  • To evaluate the pharmacokinetics of Ha44 Gel in a subset of children 2-12 years of age and adults ≥ 18 years of age

  • Trial Location2 sites in USAExpected Duration of the TrialThe trial is expected to in completed in 9 monthsCommercial PartnersNoneSponsorHatchtech Pty LtdAbout HatchtechHatchtech Pty Ltd is a venture-backed specialty pharmaceutical product company that is developing technology for the control of invertebrate pests. The company's investors include, GBS Venture Partners, Queensland Biotechnology Fund, Uniseed, University of Melbourne Endowment Trust, Westscheme and OneVentures Innovation Fund. The OneVentures Innovation Fund is supported by the Australian Government through the IIF program. The IIF is an Australian Government venture capital initiative that has supported Hatchtech

    The company's lead product is DeOvo™, a class leading head lice control agent that aims to overcome the frustrating, costly and inconvenient cycles of re-treatment experienced currently by children and their parents.

    Hatchtech
    '/>"/>

    SOURCE Hatchtech Pty Ltd
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
    4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
    5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
    7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
    8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
    9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
    10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
    11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... /PRNewswire-iReach/ -- Gateway Analytical announced today that they ... Annual Global Pharma Manufacturing Summit in ... The Global Pharma Manufacturing Summit offers a networking ... biologic pharmaceutical manufacturing. The conference is focused on ... such as the increasing pressure to grow and ...
    (Date:8/28/2014)... Orthopaedics, the Official Joint Replacement Products of the PGA TOUR ... to golf fans at the next stop of the FedEx ... company,s fan destination – "The Stryker Mobility Zone" – will ... TPC Boston in Norton, MA starting ... the Deutsche Bank Championship, Stryker will be providing golf fans ...
    (Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... ADHD Therapeutics to 2020 - Broadened ... to Drive Market Growth despite Patent ... ADHD Therapeutics to ...
    Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8
    (Date:8/29/2014)... CA (PRWEB) August 29, 2014 According ... a lawsuit against Pfizer Inc., Greenstone LLC and Pfizer ... with congenital birth defects as a result of ... defect lawsuit was filed in St. Clair County Circuit ... to the lawsuit, the defendant companies allegedly concealed the ...
    (Date:8/29/2014)... 2014 Under Section 946.300, Qualifications for ... “The physician shall not…advertise in a cultivation center or ... What the state of Illinois has done is create ... potential patients entering their care. The goal is to ... pharmacies and with typical prescription medications. Medical steering is ...
    (Date:8/28/2014)... FL (PRWEB) August 29, 2014 ... that brings pharmaceutical industry precision to the development ... zoning approval for its primary location in Sarasota ... and decisively with a total commitment to attracting ... forward to creating," says David Wright, President and ...
    (Date:8/28/2014)... Arlington, Massachusetts (PRWEB) August 29, 2014 ... company that solves some of the healthcare industry's ... design concepts that radically rethink health. Involution ... edge of technology creating software solutions for clients ... and Walgreens. , As part of the studio's ...
    (Date:8/28/2014)... UWDress.com, an internationally famous designer and leader ... fashionable assortment of fall bridesmaid dresses for ... customers, the company is now providing big discounts for ... fall bridesmaid outfits are offered in many fashionable colours. ... priced less than $190. UWDress.com’s kind officials always take ...
    Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:Medical Marijuana Company Provides Solution for Illinois Marketing Regulations 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Top Three Open Source Design Concepts that Rethink Health from Involution Studios 2Health News:Top Three Open Source Design Concepts that Rethink Health from Involution Studios 3Health News:Fashionable Fall Bridesmaid Dresses From UWDress.com 2
    ... primary biliary cirrhosis may lead to new treatments, researchers ... have found genetic variations that appear to increase the ... that can destroy the liver. , Primary biliary cirrhosis ... in the liver. It is a condition that mostly ...
    ... BEER-SHEVA, ISRAEL, June 10, 2009 Metoclopramide, a drug approved ... significant risks for the fetus according to a large cohort ... New England Journal of Medicine , "The Safety of ... Engl J Med 2009;360:24 June 11, 2009). According ...
    ... , WASHINGTON, June 10 Trust for America,s Health (TFAH) ... and Pensions (HELP) for including strong prevention and public health ... health of Americans. , , "Our nation will ... do a better job of keeping Americans healthier and preventing ...
    ... Survey Conducted with American Dietetic Association Shows Lack of Reimbursement ... June 10 Ninety-six percent of primary care physicians believe ... nutrition to treat and manage chronic disease, according to a ... currently pay significant attention to nutrition in the context of ...
    ... Researchers at The Wistar Institute have defined a key ... process of aging. The study, published June 11 in ... of aging that could point toward new anti-aging strategies ... that a class of proteins called sirtuins promotes fitness ...
    ... 10 RPD Media Associates, LLC, a full-service video content marketing ... , , ACW recognized RPD Media for producing: an ... Westchester Orthopaedic Institute; a radio spot series for WHUD ... Minute ; a feature film for The Snowball Gala ...
    Cached Medicine News:Health News:Genetic Links to Rare Liver Disease Found 2Health News:Genetic Links to Rare Liver Disease Found 3Health News:Off-label morning sickness drug deemed safe for fetuses -- Ben-Gurion U. researchers 2Health News:TFAH Applauds 'Affordable Health Choices Act' for Making Prevention a Cornerstone of Health Reform 2Health News:TFAH Applauds 'Affordable Health Choices Act' for Making Prevention a Cornerstone of Health Reform 3Health News:TFAH Applauds 'Affordable Health Choices Act' for Making Prevention a Cornerstone of Health Reform 4Health News:More Than 9 in 10 Primary Care Physicians Say U.S. Health Care System Should Place Greater Emphasis on Nutrition to Manage Chronic Disease 2Health News:More Than 9 in 10 Primary Care Physicians Say U.S. Health Care System Should Place Greater Emphasis on Nutrition to Manage Chronic Disease 3Health News:More Than 9 in 10 Primary Care Physicians Say U.S. Health Care System Should Place Greater Emphasis on Nutrition to Manage Chronic Disease 4Health News:Wistar Institute team finds key target of aging regulator 2Health News:RPD Media Wins Four 'Big W' Awards by the Advertising Club of Westchester County 2
    Intended for the quantitative determination of creatinine in serum, plasma, or urine. Reaction: Endpoint. Wavelength: 340 nm. Linearity: 10 mg/dL (880 mol/L). Two vials, dry powder reagents....
    For the qualitative determination of magnesium in serum....
    Intended for the quantitative determination of magnesium in serum. Wavelength: 340 nm. Linearity: 9.7 mg/dL (4 mmol/L). Two vials, dry powder reagents....
    For the quantitative determination of total glucose in serum....
    Medicine Products: